There are no approved vaccines for HSV, and GSK’s decision to stop developing ... an investigational vaccine for herpes simplex virus type 2. The candidate is currently in phase 1/2 trial ...

GSK has abandoned its clinical-stage vaccine for herpes simplex virus (HSV) after a disappointing phase 1/2 trial, ceding the ground to mRNA shots in development at Moderna and BioNTech.

Moncef Slaoui, who ran the Operation Warp Speed Covid vaccine effort, is becoming chair of Curevo, a company developing a new ...

buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer's Prevnar franchise. GSK said it is paying $2.1 billion upfront for ...

Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round. The ...

GSK said on Tuesday that it is studying a group of more than a million older adults in the UK to examine whether its ...

The FDA approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new ...

GSK is also working with SK Bioscience on a phase 1/2 study for a vaccine based on self-assembling nanoparticle technology developed by the University of Washington, with funding from CEPI and the ...

Two earlier trials demonstrated that a vaccine based on the HSV-2 glycoprotein D subunit (gD-2) was effective in protecting HSV-1/HSV-2-seronegative women whose sexual partners had recurrent HSV ...